» Articles » PMID: 35567665

Inflammasomes and the IL-1 Family in Bone Homeostasis and Disease

Overview
Publisher Current Science
Date 2022 May 14
PMID 35567665
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: Inflammasomes are multimeric protein structures with crucial roles in host responses against infections and injuries. The importance of inflammasome activation goes beyond host defense as a dysregulated inflammasome and subsequent secretion of IL-1 family members is believed to be involved in the pathogenesis of various diseases, some of which also produce skeletal manifestations. The purpose of this review is to summarize recent developments in the understanding of inflammasome regulation and IL-1 family members in bone physiology and pathology and current therapeutics will be discussed.

Recent Findings: Small animal models have been vital to help understand how the inflammasome regulates bone dynamics. Animal models with gain or loss of function in various inflammasome components or IL-1 family signaling have illustrated how these systems can impact numerous bone pathologies and have been utilized to test new inflammasome therapeutics. It is increasingly clear that a tightly regulated inflammasome is required not only for host defense but for skeletal homeostasis, as a dysregulated inflammasome is linked to diseases of pathological bone accrual and loss. Given the complexities of inflammasome activation and redundancies in IL-1 activation and secretion, targeting these pathways is at times challenging. Ongoing research into inflammasome-mediated mechanisms will allow the development of new therapeutics for inflammasome/IL-1 diseases.

Citing Articles

Citrate: a key signalling molecule and therapeutic target for bone remodeling disorder.

Liu Q, Xue Y, Guo J, Tao L, Zhu Y Front Endocrinol (Lausanne). 2025; 15:1512398.

PMID: 39886032 PMC: 11779597. DOI: 10.3389/fendo.2024.1512398.


Butyric Acid Modulates Gut Microbiota to Alleviate Inflammation and Secondary Bone Loss in Ankylosing Spondylitis.

You K, Yang L, Su Z, Shen J, Fan X, Guo Y Biomedicines. 2025; 13(1).

PMID: 39857593 PMC: 11762490. DOI: 10.3390/biomedicines13010009.


Zoledronic Acid Inhibits Lipopolysaccharide-Induced Osteoclastogenesis by Suppressing Macrophage NLRP3-Mediated Autophagy Pathway.

Cheng Y, Liu G, Huang X, Xiong Y, Song N, An Z Immun Inflamm Dis. 2024; 12(12):e70094.

PMID: 39679857 PMC: 11647992. DOI: 10.1002/iid3.70094.


Balancing the Scales: The Dual Role of Interleukins in Bone Metastatic Microenvironments.

Dawalibi A, Alosaimi A, Mohammad K Int J Mol Sci. 2024; 25(15).

PMID: 39125732 PMC: 11311339. DOI: 10.3390/ijms25158163.


Mechanistic insights into bone remodelling dysregulation by human viral pathogens.

Caetano C, Azamor T, Meyer N, Onwubueke C, Calabrese C, Calabrese L Nat Microbiol. 2024; 9(2):322-335.

PMID: 38316931 PMC: 11045166. DOI: 10.1038/s41564-023-01586-6.


References
1.
Offenbacher S, Jiao Y, Kim S, Marchesan J, Moss K, Jing L . GWAS for Interleukin-1β levels in gingival crevicular fluid identifies IL37 variants in periodontal inflammation. Nat Commun. 2018; 9(1):3686. PMC: 6134146. DOI: 10.1038/s41467-018-05940-9. View

2.
Yamaguchi Y, Kurita-Ochiai T, Kobayashi R, Suzuki T, Ando T . Regulation of the NLRP3 inflammasome in Porphyromonas gingivalis-accelerated periodontal disease. Inflamm Res. 2016; 66(1):59-65. DOI: 10.1007/s00011-016-0992-4. View

3.
Schnellbacher C, Ciocca G, Menendez R, Aksentijevich I, Goldbach-Mansky R, Duarte A . Deficiency of interleukin-1 receptor antagonist responsive to anakinra. Pediatr Dermatol. 2012; 30(6):758-60. PMC: 3548019. DOI: 10.1111/j.1525-1470.2012.01725.x. View

4.
Ruscitti P, Berardicurti O, Cipriani P, Giacomelli R . Benefits of anakinra versus TNF inhibitors in rheumatoid arthritis and type 2 diabetes: long-term findings from participants furtherly followed-up in the TRACK study, a multicentre, open-label, randomised, controlled trial. Clin Exp Rheumatol. 2021; 39(2):403-406. View

5.
Radaic A, Kapila Y . The oralome and its dysbiosis: New insights into oral microbiome-host interactions. Comput Struct Biotechnol J. 2021; 19:1335-1360. PMC: 7960681. DOI: 10.1016/j.csbj.2021.02.010. View